ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

emrusolmin

Also written as “TEV-56286”, “anle138b” and “TEV-56286 Test”.

Its studies are mostly in Multiple System Atrophy · Parkinson Disease, led by 2 companies.

Drug pageEmrusolmin: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 20, 20248 company-led studies, 3 open or runningLicense: MODAG → Teva, Oct 2021Next primary completion: Jan 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industries53 open or runningphase 2since Aug 20, 2024Aug 20, 2024Jan 15, 2027phase 1 · NCT07674940
MODAGits history only30 open or runningphase 1since Dec 16, 2019Dec 16, 2019none ahead

Also a collaborator on its studies: Aptuit and Quotient Sciences.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Teva Pharmaceutical Industries only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2021Teva licensed it from MODAGLicenseWorldwide rights · announced · Teva and MODAG (release)
  2. Jan 25, 2022Named emrusolminINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TEV-56286
  3. Aug 20, 2024First study: phase 2 study in Multiple System AtrophyFirst studyNCT06568237 · 349 enrolled · United States, France, Germany and more
  4. Oct 2, 2024Phase 1 study in Healthy ParticipantsNCT06627231 · 8 enrolled · Netherlands
  5. Mar 28, 2025Phase 1 study in Healthy ParticipantsNCT06911567 · 47 enrolled · United States
  6. Sep 26, 2025Phase 2 study in Multiple System AtrophyNCT07197866 · 200 planned · United States, France, Germany and more
  7. Jun 23, 2026Phase 1 study in Healthy VolunteersNCT07674940 · 69 planned · United States

Ahead

  1. Jan 15, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07674940
  2. Sep 15, 2027Primary completion: phase 2 study in Multiple System AtrophyNCT06568237
  3. May 3, 2029Primary completion: phase 2 study in Multiple System AtrophyNCT07197866

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 Teva Pharmaceutical Industries leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07674940Healthy Volunteers · United States1RecruitingJan 15, 202769
NCT07197866Multiple System Atrophy · United States, France, Germany and more2RecruitingMay 3, 2029200
NCT06911567Healthy Participants · United States1CompletedMay 22, 202547
NCT06627231Healthy Participants · Netherlands1CompletedNov 29, 20248
NCT06568237Multiple System Atrophy · United States, France, Germany and more2Active, not recruitingSep 15, 2027349

How it is read

Names in the registry

  • “TEV-56286”, 4 entries
  • “anle138b”, 2 entries
  • “TEV-56286 Test”, 1 entry
  • “TEV-56286 Reference”, 1 entry
  • “anle138b (TEV-56286)”, 1 entry

Codes read as this program: TEV56286.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.